The Defence Minister of Russia, Sergei Shoigu, said on 27 November 2020 that Russia plans to vaccinate over 400,000 military personnel against COVID-19, as authorities reported a record 27,543 new COVID-19 cases, Reuters news agency reported on Friday.
News agencies cited Shoigu as saying that 2,500 military personnel had been vaccinated against COVID-19 already, with the total expected to reach 80,000 by the end of the year.
Russia, which is working on several vaccines against COVID-19, has reportedly seen a surge in COVID-19 infections since September 2020 but authorities have resisted imposing lockdowns, relying instead on targeted measures in certain regions.
Indian pharmaceutical company Hetero will manufacture over 100 million doses of Russia's Sputnik V COVID-19 vaccine per year under the terms of a deal with Russia's RDIF sovereign wealth fund, which was unveiled on Friday.
Siberia's Vector Institute, developing EpiVacCorona, Russia's second COVID-19 vaccine, is ready to produce up to five million doses of its vaccine per year, Alexander Ryzhikov, head of the institute's zoonotic infections and influenza department, said on Friday.
Russia, with 2,215,533 COVID-19 infections, has the fourth-largest number of COVID-19 cases in the world behind the US, India and Brazil. It has recorded 38,558 deaths related to COVID-19 since the start of the pandemic.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100